New injection aims to slow vision loss from dry AMD

NCT ID NCT07392255

Recruiting now Disease control Sponsor: Complement Therapeutics Source: ClinicalTrials.gov ↗

First seen Feb 06, 2026 · Last updated May 23, 2026 · Updated 24 times

Summary

This study tests a single injection of CTx001 into the eye for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. The goal is to see if it is safe and can slow vision loss. About 75 participants will be followed for up to 5 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Gundersen Health System
RECRUITING

La Crosse, Wisconsin, 54601, United States
Midwest Eye Institute
RECRUITING

Carmel, Indiana, 46290, United States
Retina Foundation of the Southwest
RECRUITING

Dallas, Texas, 75231, United States
Sierra Eye Associates
RECRUITING

Reno, Nevada, 89502, United States

Conditions

Explore the condition pages connected to this study.

GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION